Autoimmune diseases, including inflammatory arthritis, are characterized by a loss of self-tolerance, leading to an excessive immune responses and subsequent ongoing inflammation. Current therapies are focused on dampening this inflammation, but a permanent state of tolerance is seldom achieved. Therefore, novel therapies that restore and maintain tolerance are needed. Tregs could be a potential target to achieve permanent immunotolerance. Activation of Tregs can be accomplished when they recognize and bind their specific antigens. HSPs are proteins present in all cells and are upregulated during inflammation. These proteins are immunogenic and can be recognized by Tregs. Several studies in animal models and in human clinical trials have shown the immunoregulatory effects of HSPs and their protective effects in inflammatory arthritis. In this review, an overview is presented of the immunomodulatory effects of several members of the HSP family in general and in inflammatory arthritis. These effects can be attributed to the activation of Tregs through cellular interactions within the immune system. The effect of HSP-specific therapies in patients with inflammatory arthritis should be explored further, especially with regard to long-term efficacy and safety and their use in combination with current therapeutic approaches.
Introduction
RA and JIA are characterized by persistent inflammatory synovitis, resulting in destruction of joint cartilage and bone, functional disability, decreased quality of life and cardiovascular disease [1, 2] . The fundamental problem in autoimmune diseases, such as RA and JIA, is faulty regulation of the inflammatory process. The immune system of healthy people is populated with T cells and B cells expressing receptors that can bind self-antigens. Chronic activation of these self-reactive lymphocytes results in chronic inflammation. Failure of the immune system to downregulate these potentially dangerous cells leads to autoimmune diseases. Therefore, a rational therapeutic goal in diseases of unregulated inflammation is to re-establish physiological regulation. Competing targeted therapeutics, such as anti-CD3, CTLA4-Ig, anti-TNF-a or B celldepleting antibodies, are oriented towards suppression of the inflammatory response. Therefore they are less safe, more costly in side effects and do not address the fundamental problem, a disturbed immune tolerance.
HSPs have been increasingly studied in inflammatory arthritis models and could be a potential new therapeutic target, as they appear to be involved in immune tolerance in a physiological manner. It seems as if the immune system is poised towards HSP recognition, with a natural inclination towards control of inflammatory responses. In this review we will summarize the immunoregulatory function of HSPs and their role in diseases like RA and JIA. We will also discuss how these properties can be translated into new therapies and summarize the trials that have already been performed in this field.
HSPs and immune regulation
In systemic autoimmune diseases, immunological selftolerance is disturbed. This results in chronic inflammatory responses directed towards self-tissues. Several cells and parts of the immune system are thought to play a role in the maintenance of self-tolerance and a balanced immune response.
Roughly 20 years ago it was discovered that so-called Tregs are critical for the development of immunological tolerance. Tregs are part of our adaptive immune system, as they are a subset of specialized CD4 + Th cells defined by the expression of the IL-2 receptor achain (CD25) and the transcription factor FoxP3 [3] . It is thought that in healthy organisms these cells control selfreactive or exaggerated immune responses. Impaired Treg function has been identified in diseases like RA and diabetes mellitus type 1 [4] . Treg activation is antigen dependent. Activation is established when an antigen bound in the antigen binding cleft of an MHC class II molecule, presented by an antigen-presenting cell (APC), binds to the T cell receptor, in conjunction with appropriate co-stimulatory molecules. When activated by their specific antigen, Tregs produce anti-inflammatory cytokines or start other mechanisms that lead to inactivation of the effector cells, leading to inhibition of the inflammatory reaction [57] .
Tregs are important in the control of autoimmunity [8] . Targeting these cells is an important new focus of immunotherapeutic approaches in autoimmune diseases. Since Tregs are antigen specific, there is good reason for the use of their specific antigens for triggering their actions. Previous research has indicated that HSPs can serve as an antigen. Several family members of the HSPs form selfantigens that can activate disease-suppressive Tregs. We will further introduce this family of proteins and summarize their role in immune responses, including their interaction with Tregs.
HSPs are housekeeping proteins found in all living organisms. They are highly conserved proteins with high homology between mammalian and microbial HSPs. The family members are classified according to their molecular weight (e.g. HSP60 is 60 kDa). Major HSP families are HSP40, HSP60, HSP70, HSP90, HSP100 and the small HSP family (2025 kDa). They function as intracellular chaperones involved in several intracellular processes. Their main role is protein folding. Furthermore, they are associated with peptide binding to MHC molecules, protein synthesis and transport. HSP10 and HSP40 function as co-chaperones for HSP60 and HSP70, respectively [9, 10] . The HSP70 family is large and contains at least eight chaperone proteins. Most eukaryotes have several different HSP70 proteins, found in a variety of cellular compartments. For instance, binding immunoglobulin protein (BiP) can be found in the endoplasmic reticulum, while HSC70 is found in the cytoplasm [11, 12] . An overview of the mentioned HSP members is provided in Table 1 . HSPs are ubiquitously expressed and are upregulated during inflammation, necrosis and exposure to heat stress or toxic treatments [13, 14] . Several studies have shown that these proteins are immunogenic and can be recognized by cells of both the innate and adaptive immune systems [15] .
As HSPs are self-antigens present in our own cells, it is remarkable that they are recognized by our immune system and generate immunological reactions. It seems as if the immune system has a vested interest in responding to these proteins. A possible explanation is that proteins like HSPs have a signal function, alarming the immune system when tissues are stressed due to infection or inflammation [17] . There is evidence that HSPs can activate the innate immune system by binding as pathogen-associated molecular patterns to certain Toll-like receptors (TLRs), which are present on dendritic cells and macrophages. HSP60 activates Tregs via TLR2 [18] . Extracellular HSP70 can regulate innate immune cell function, binding to cell surface receptors through TLR2 and TLR4 to induce IL-10 production [19, 20] .
Given the fact that these cells are APCs, the adaptive immune system can be activated in this way as well. However, HSP60 and HSP70, the most well-studied HSPs, have also been found in the circulation of healthy individuals [21] . The seemingly contradictory nature of some of the effects of HSPs on the immune system is still open for further studies. Accumulating findings, however, indicate that HSPs have potential for the attenuation or regulation of inflammatory responses and can be seen as key players involved in the homeostasis that controls autoimmunity [2226] . In support of that possibility are the more recent findings on anti-inflammatory responses, by activating Tregs and increasing IL-10 release [10, 18, 2729] .
The mechanisms of Treg activation by several HSP members have been investigated in in vitro studies and animal models. Many experiments with regard to HSPs have been performed with microbial HSPs. It is known that because HSPs are highly conserved molecules, the molecular structure of mammalian (human) and microbial HSPs is very similar. At the level of the adaptive immune system, this can lead to cross-reactivity. Thus this crossreactivity induced by exposure to microbial HSPs during an infection or in an artificial way (e.g. immunization) can lead to activation of self-HSP-reactive T cells and subsequently to immunoregulatory activities, as already mentioned [3032] .
In conclusion, several members of the HSP family are able to regulate immune responses and activate Tregs via both the innate and adaptive immune systems.
HSPs in inflammatory arthritis
Until now, the exact role of HSPs in autoimmune diseases like inflammatory arthritis has not been clearly defined. In earlier studies, both pro-inflammatory and antiinflammatory effects induced by several HSP families were described [33] . A likely explanation for this is that studies performed with HSPs that produced pro-inflammatory effects were performed with recombinant HSPs produced in bacteria. Bacterial contaminants are thought to be responsible for the described pro-inflammatory effects. In the www.rheumatology.oxfordjournals.org absence of foreign pathogen-associated molecular patterns, using purified bacterial HSPs, there is often no pro-inflammatory effector response [3437] . Previously we discussed some of the controversies related to the possible function of HSPs as damage-associated molecular patterns [38, 39] .
In arthritis, inflammation in the joint leads to cellular stress and upregulation of self-HSPs in the synovial tissue. Several studies have shown a significantly higher percentage of cells featuring HSP60 and HSP70 membrane expression among fibroblast-like synovial cells derived from arthritis-affected joints in RA and JIA patients compared with those obtained from healthy controls [4042] . Two studies investigating HSP70 in RA patients show that self-HSP70 was released from fibroblast-like synovial cells in response to TNF-a, which functions as an inflammatory stressor. HSP70 induced IL-10 production in these fibroblasts via TLR4 and downregulated IL-6 and IL-8 via several signal transduction pathways [43, 44] . Furthermore, it seems that T cells from the SF and peripheral blood leucocytes of patients with JIA or RA proliferate in response to mycobacterial HSP60 and HSP70 [45] . In patients with JIA, cells had substantial proliferative responses to self-HSP60, mycobacterial HSP60 and other HSPs, including HSP dnaJ (HSP40) [4648] .
Another study showed that serum concentrations of soluble HSP60 were increased in both active and inactive oligo-and polyarticular disease in JIA patients. Interestingly, the serum concentrations correlated positively with the time required for remission from flare-ups [49] . This might imply that the presence of high levels of soluble HSP60 reflects a high degree of inflammation or tissue damage and could have prognostic value. Although this might suggest a possible role of soluble protein in the pathogenic mechanism of the disease, studies have shown that patients with JIA developing immune responses to human or mycobacterial HSP60 or human HSP40 had a favourable prognosis. In oligoarticular JIA, remission was associated with a significant T lymphocyte proliferative response to human HSP60 [50, 51] . In a subsequent study, it was shown that T cells recognizing self-HSP60, isolated from JIA patients, express CD25 and CD30 and produce regulatory cytokines like IL-4 and IL-10 [52]. These results suggest that T lymphocyte reactivity to HSP60 may be part of the T cell regulatory mechanisms that control the development of arthritis.
In studies with RA patients, similar observations were made. With regard to HSP60, we found that SF T cells reactive to human HSP60 produced more IL-4 and less IFN-g when stimulated with bacterial HSP60 [53] . In studies with human and bacterial HSP40, it was found that these proteins inhibited CD4 + and CD8 + T cells and stimulated the secretion of IL-10. Also, HSP40 reduced TNF-a secretion [54, 55] . Concerning HSP70, potent disease-suppressive Tregs recognizing self-HSP70 have been found. In a recent study by van Herwijnen et al. [56] it was revealed that antigen-specific Tregs bind the conserved HSP70 epitope 141155 of mycobacterial HSP70 (B29) in mice and that the endogenous HSP70 homologs activate these cells in vivo. It was shown that this conserved HSP70 epitope (B29) could naturally be bound by murine MHC class II. In a subsequent study, this B29 epitope showed a high binding affinity of all homologous peptides for the RA-associated HLA-DR4 and HLA-DQ8 molecules [57] . Upon transfer, B29-induced CD4 + CD25 + Foxp3 + T cells suppressed established proteoglycan-induced arthritis in mice. When using lymphocyte activation gene-3 as a selection marker, as few as 4000 cells sufficed to fully suppress arthritis. Furthermore, antibody-mediated in vivo depletion of transferred Tregs abrogated disease suppression. Transferred cells exhibited a stable phenotype and were found in joints and draining lymph nodes up to 2 months after transfer [56] . Another member of the HSP70 family, which deserves special attention, is BiP. This stress protein has been investigated for its immunomodulatory properties in patients with RA. In earlier studies, autoantibodies to BiP were found in the majority of RA patients [58] . Similar to other HSPs, BiP is overexpressed in synovial tissue of patients with RA. In addition, some findings in relation to BiP have been contradictory, as there were studies that found BiP stimulated T effector cells and therefore has a role in RA pathogenesis [59, 60] . Not much is known about the change in serum HSP levels during the course of disease. Only one small study reported a difference in serum levels of HSP70 in patients with RA in high and low disease activity [61] . It seems that by recognizing self-HSPs in the inflamed joint, Tregs are activated, producing immunomodulating cytokines, which may diminish inflammation and thus local joint damage (Fig. 1) . This makes immunotherapy with HSPs a potential new strategy for Treg-promoting interventions.
HSP as a therapeutic strategy in arthritis
The administration of several HSP family members, HSPderived peptides or altered peptide ligands has been studied in relation to arthritis therapy, both in animals or in vitro using cells of JIA and RA patients, and some were even tested in vivo in clinical trials for RA (Tables 2 and 3 ). We will now summarize the results of these studies.
In vitro studies with cells from RA patients show a decrease in pro-inflammatory and an increase in antiinflammatory cytokine production when peripheral blood mononuclear cells (PBMCs) were stimulated with HSP60 [89] . Remarkably, in most cases this effect was not seen in healthy controls.
Another in vitro study tested altered peptide ligands derived from a CD4 + T cell epitope of human HSP60
(APL-1) on PBMCs, which showed an immunomodulating effect [90] . APL-2 showed similar results in PBMCs from RA patients [73] . APLs are peptides similar to the original epitopes but with alterations in the contact positions with the T cell receptor necessary for activation of these cells [92] . This results in different phenotypes of T cell activation. The effect of APLs on T cells may range from partial activation to complete turn-off of their functional capacity (anergy). As was also demonstrated in models of arthritis, the effects of APL, including HSP60-based APL, can be a combination of competition for MHC binding or T cell inhibition, but also induction of immune regulation, since APL immunization sometimes led to prevention of subsequently induced disease [93] .
In studies with adjuvant-induced arthritis (AIA) in rats, it was recognized that priming of self-HSP60-directed T cells led to protection against arthritis instead of disease induction or aggravation. Furthermore, immunization of rats with synthetic peptides derived from human or microbiological HSP60 (which are cross-reactive) led to protection against AIA, suppression of pro-inflammatory cytokines and an increase of anti-inflammatory cytokines [74, 89] . The effects of a combination therapy with HSP60 and a low-dose anti-TNF-a were investigated as well. A single low dose of anti-TNF-a, which in itself did not suppress disease, was combined with intranasal HSP60 peptide from heat-killed Mycobacterium tuberculosis in AIA rats and was therapeutically effective [77] . Similar therapeutic effects were accomplished with administration of mycobacterial or self-HSP70 in several experimental disease models [29, 83, 84, 86, 98, 99] . Some of these effects were thought to be facilitated by HSP modulation of the APCs, which influences the nature of the cytokine response and supports the anti-inflammatory role of this protein [99] .
BiP, an HSP70 family member, was studied in vitro in PBMCs of patients with RA. The cells were found to proliferate and produce mostly pro-inflammatory mediators such as IL-1 when stimulated with BiP. On the other hand, incubation of monocytes with BiP downregulated
FIG. 1 HSP-based vaccines enhance regulatory activity through expansion of HSP-cross-reactive T cells and activation of self-HSP-specific Tregs (A) Immunization with microbial HSP. (B)
Immunoregulatory response at the site of inflammation after immunization.
www.rheumatology.oxfordjournals.org CD86 and HLA-DR expression. Similar responses were found in a study using RA synovial membrane transplants in severe combined immunodeficiency mice [91, 100] . The underlying mechanism for the latter effect seems to be based on the activation of tolerogenic dendritic cells (tolDCs) and subsequent generation of Tregs [101] . Similar versatile effects of BiP occurred in a recent study, which showed that effector and Treg cells recognize different BiP epitopes. In vitro, two BiP epitopes were tested on PBMCs of RA patients. One epitope (BiP 336355) led to strong proliferation of the PBMCs, correlating with disease activity, while the other epitope (BiP 456475) had an anti-inflammatory effect. This last epitope was further examined by oral administration in mice with CIA. A reduction in T cell proliferation and arthritis was found in this group, as well as increased secretion of IL-10 from T cells [88] . We described the immunomodulating effects of different HSP members in arthritis animal models or in in vitro studies with cells from patients with RA or JIA. These proteins could be a potential therapeutic target for tolerancepromoting interventions in rheumatic diseases. Given the physiological role of HSPs in healthy immune regulation, the effects of HSPs on inflammation reported in several studies could be a manifestation of a state of permanent immunotolerance rather than temporary immunological control. An attractive benefit of targeting HSP-specific Tregs is that effects are guided towards sites of inflammation where HSPs are expressed and thus induction of systemic immunosuppression may be avoided.
Clinical trials with HSP-based immunotherapy
Until now, only a few clinical trials with HSPs have been reported. The first HSP tested in the clinic in a phase I trial was with dnaJP1 in 15 patients with early RA. Mucosal administration of dnaJP1 during 6 months led to a shift in T cells from a pro-inflammatory to a regulatory phenotype. Three different dosages were tested: 0.25, 2.5 and 25 mg/ day. There were no important side effects reported [94] . Koffeman et al. [95] performed a placebo-controlled phase II/III trial with dnaJP1 in 160 RA patients. After daily oral administration with 25 mg over 6 months, a trend towards clinical improvement was seen. The treatment was reported as safe and well tolerated. The only side effect reported was a self-remitting leukopenia in six patients. The short-term effects of intravenous administration of HSP10 were investigated in a randomized, double-blind, multicentre study. In this study with 23 treatment-resistant RA patients, chaperonin 10 was given twice weekly for 12 weeks at doses of 5, 7.5 or 10 mg. Disease activity scores improved significantly during the 12 weeks of therapy in the high-dose group. Most adverse events were reported to be mild or moderate; seven patients recorded an RA flare and recurrent upper respiratory tract infections were common. One patient had severe myalgia [96] .
Currently a first phase I/IIa clinical trial with BiP in RA patients is being carried out and the results will be made public soon (Corrigall V, personal communication) . But m ore trials are needed, especially with regard to longterm efficacy and safety and use in combination with current therapeutic approaches.
Targeting Tregs in inflammatory arthritis and Treg resistance
A point of concern about the expected efficacy of tolerance induction therapy by targeting Tregs in the clinical practice is the fact that these cells may have altered functions in patients with inflammatory arthritis. Besides the disturbed activation of T effector cells and proinflammatory stimuli, several studies point out that Treg function is impaired and that they are unable to suppress pro-inflammatory cytokine production [1, 4, 102]. One underlying mechanism that explains the altered functioning of Tregs in inflammatory arthritis involves the canonical Wnt pathway. T cell factor 1 is a Foxp3 interaction partner and modulates transcriptional activity of Foxp3. T cell factor 1 is regulated by canonical Wnt signalling. Activation of the Wnt pathway reduced Treg-mediated suppression in in vitro and in vivo experiments. Activation of effector T cells increased Wnt3a production and Wnt3a levels were found to be elevated in mononuclear cells isolated from the SF of arthritis patients. Therefore, Wnt signalling directly modulates FoxP3 activity and thereby Treg cell function [103] . Furthermore, the inflammatory environment may lead to Treg dysfunction in these patients [104] . Altered Treg functions caused by pro-inflammatory stimuli might indicate the need for a pretreatment or a combination of medication to optimize the effective targeting of Tregs, as we will discuss below.
Considerations for therapy in the clinic
In general, long-lasting peripheral immune tolerance could be established by repetitive administration of a specific self-antigen. Although such a specific disease-inducing antigen is not known for diseases such as RA and JIA, the studies discussed in this review suggest that several Chaperonin 10 RA, n = 23 Intravenous, 12 weeks Clinical improvement of disease activity [96] www.rheumatology.oxfordjournals.org HSP members could be used as antigens to induce such an effect. In fact, since this immune response is achieved by activating elements of a self-reactive repertoire of T cells that is part of the adaptive immune system, immunological memory could be established, similar to what happens in vaccination. Given the versatile effects of whole protein, one should consider the use of selected peptides derived from the whole proteins to reach a more specific immunomodulation. Several studies have indicated how a translational path from animal models to the clinic has led to the proper selection of peptides for human application [105107] . The route of administration to induce immune tolerance with HSP is a point of debate. To our knowledge no studies have been performed investigating the superiority of oral administration to other routes. Theoretically, mucosal delivery would be a more appropriate way because it mimics the natural routes of tolerance induction [108] . Furthermore, mucosal administration of antigen might be a safer route compared with subcutaneous delivery since subcutaneous administration of antigens in general could lead to hypersensitivity reactions [109] .
A recent addition to the immunotherapeutic armamentarium directed at restoring immune tolerance in RA is treatment with autologous tolDCs. Their therapeutic potential has been demonstrated in experimental animal models of autoimmune disease, including RA [110112] . Results from the first clinical trials were published recently. In a small, phase I, open-label trial in patients with RA, intradermal administration of autologous modified DCs exposed to citrullinated peptides appeared to be safe and biologically active [113] . Another phase I trial in RA patients, the results of which have not yet been published, is using tolDCs loaded with autologous SF [114] .
With regard to the choice and source of the antigen used to modify DCs to target autoantigen-specific T cells, several remarks can be made. As mentioned before, no universal autoantigen has been identified in RA. In both studies mentioned above, similar to HSPs, the target antigens are specific for the inflammation itself and mainly present at the site of inflammation (the synovium). However, when using citrullinated peptides as an autoantigen, only RA patients with ACPAs are qualified to receive this treatment. Using autologous SF might cover a broad spectrum of antigens, but has the disadvantage that monitoring of the immunological effect with specific antigens would be challenging. Furthermore, SF is not available from early RA cases, the group that would qualify best for tolerance-promoting interventions. Here, HSP would offer obvious advantages, including the possible standardized production of its derivative peptides.
HSP treatments in inflammatory diseases may potentially be safe and effective since their recognition as modulators of inflammation is built into the immune system-HSP treatment is not an artificial immune processor but a natural regulator selected by evolution. Moreover, the immune system is primed to respond to HSP molecules and their epitopes by combined adaptive and innate receptor systems; the adaptive and innate effects are synergistic for enhanced recognition. It may well be that we are seeing the beginning of a very novel approach of immunomodulatory vaccination in autoimmunity, which may lead to novel treatments as well prophylactic modalities. More clinical trials will be necessary to reveal further aspects, such as long-term efficacy and safety, as well as to examine the optimal dose, route and time point of administration and possible combination with other immunosuppressive or immunomodulatory agents.
Conclusion
In this review we provided an overview of the immunomodulatory effects of several members of the HSP family in general and in inflammatory arthritis. These effects can be attributed to the activation of Tregs. HSPs can induce an immunomodulatory effect in vitro in PBMCs from patients with RA and JIA and in vivo in experimental animal models with AIA. There are a few clinical trials that show some first promising effects of HSP administration in patients with RA. The effect of HSP-specific therapies should be explored further, especially with regard to long-term efficacy and safety and their use in combination with current therapeutic approaches. 
